ClinicalTrials.gov

Registration and Results Reporting

NIH POLICY (2016)

Scope and Applicability

Definition

Responsible Party

DHHS FINAL RULE (2016)

Definition

Responsible Party

Laverne Estanol, M.S., CHRC, CIP, CCRP
Assistant Director, Human Research Protections
The **NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information** covers all applications for funding (including grants, contracts, and other transactions) submitted **on or after January 18, 2017** that request support for the conduct of any clinical trial. 2 The policy **does not apply** to clinical trials in ongoing, non-competing awards, but will apply if the grantee submits a competing renewal application that includes a new clinical trial. 2 The policy **does not apply** to a clinical trial that uses NIH-supported infrastructure but does not receive NIH funds to support its conduct. 3

Although the policy **does not apply** to NIH-funded clinical trials initiated before the effective date, NIH encourages all ongoing NIH-funded clinical trials to follow **this policy**. 4 Investigators conducting NIH-funded applicable clinical trials that are **subject to the statute*** and **rule**** also need to be in compliance with those requirements. 4, 5

The policy **applies**:
- to all applications for funding (including grants, contracts, and other transactions) submitted **on or after January 18, 2017** that request support for the conduct of any clinical trial
- if the grantee submits a competing renewal application that includes a new clinical trial

The policy **does not apply** to:
- clinical trials in ongoing, non-competing awards
- a clinical trial that uses NIH-supported infrastructure but does not receive NIH funds to support its conduct
- NIH-funded clinical trials initiated before the effective date

---

2 https://grants.nih.gov/policy/clinical-trials/reporting/faq.htm#5053
5 HHS Agencies (includes NIH): https://www.hhs.gov/about/agencies/hhs-agencies-and-offices/index.html
* FDAAA, ** Final Rule / 42 CFR Part 11

Specific to a funding opportunity announcement (FOA)
A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.

1 https://www.federalregister.gov/d/2016-22379/p-70
2 https://grants.nih.gov/policy/clinical-trials/definition.htm

Unpacking the definition (slides 5 & 6): https://grants.nih.gov/sites/default/files/Clinical-Trials-Changes-full%20length_v5.pptx


FAQs: https://grants.nih.gov/grants/policy/faq_clinical_trial_definition.htm

March 2018 - possible update to definition for basic behavioral research:
NIH POLICY

Responsible Party 1, 2, 3

NIH-Funded Clinical Trial is subject only to the NIH Policy:

- The recipient or investigator

NIH-Funded Clinical Trial is subject to the DHHS Final Rule:

- The Sponsor, or
- The Principal Investigator, if designated by the sponsor, grantee, contractor, or awardee

Registration at ClinicalTrials.gov: within 21 days after enrollment of the first research participant 4

Results Submission at ClinicalTrials.gov: within 12 months after primary completion date 5

2 https://grants.nih.gov/policy/clinical-trials/reporting/steps.htm#
3 https://www.federalregister.gov/d/2016-22379/p-74
4 https://clinicaltrials.gov/ct2/manage-recs/faq#fr_5
5 https://clinicaltrials.gov/ct2/manage-recs/faq#fr_7


Noncompliance (page 6), 2016 NEJM article: The FDAAA and the NIH policy hold all parties responsible for clinical trials (not just the individual investigators) accountable. [DOI: 10.1056/NEJMsrr1611785]
Applicable Device Clinical Trial
1) Controlled trials with health outcomes of devices subject to FDA regulation, other than small feasibility studies, and 2) pediatric postmarket surveillance required by FDA

Applicable Drug Clinical Trial
Controlled clinical investigations, other than phase 1 clinical investigations, of drugs or biological products subject to Food and Drug Administration (FDA) regulation

A note about Expanded Access
Information on the availability of investigational drug products (including biological drug products) for expanded access will continue to be required to be submitted to the Clinical Trials.gov database. 4

2 https://clinicaltrials.gov/ct2/manage-recs/fdaaa#WhichTrialsMustBeRegistered
3 https://grants.nih.gov/clinicaltrials_fdaaa/docs/Flow_chart-ACT_only.pdf

FAQs: https://clinicaltrials.gov/ct2/manage-recs/faq
The Sponsor, or
The Principal Investigator, if designated by the sponsor, grantee, contractor, or awardee

Final Rule: effective January 18, 2017 / compliance date of April 18, 2017

Registration at ClinicalTrials.gov: within 21 days after enrollment of the first research participant

Results Submission at ClinicalTrials.gov: within 12 months after primary completion date

FAQs: https://clinicaltrials.gov/ct2/manage-recs/faq

Registration & Results submission - table (prior to 2007, and on/after effective date of final rule): https://www.federalregister.gov/d/2016-22129/p-961


Noncompliance (page 6), 2016 NEJM article: The FDAAA and the NIH policy hold all parties responsible for clinical trials (not just the individual investigators) accountable. [DOI: 10.1056/NEJMsr1611785]
Human Research meets conditions of the NIH Policy

Register at ClinicalTrials.gov within 21 days of enrollment of first research subject

Submit Study Results at ClinicalTrials.gov within 12 months after completion of research study

Human Research meets conditions of the DHHS Final Rule

Register at ClinicalTrials.gov within 21 days of enrollment of first research subject

Submit Study Results at ClinicalTrials.gov within 12 months after completion of research study
School of Medicine clinical trials: Mark Bourbonnais (Mbourbon@hs.uci.edu, 949-682-5440)

Non-School of Medicine clinical trials: Laverne Estanol (Lestanol@uci.edu, 949-824-4704)